Diana serves as a Director, Innovation Policy at Pfizer where she leads policy development for issues related to clinical trials, including enrollment, diversity, and data sharing. Diana also serves as the policy lead for issues related to patient centricity, oncology, digital health, expanded access, and supply chains. Diana’s primary interest is in the development and implementation of evidence-based science- and health-related policies.
Previously, Diana worked at the White House Office of Science and Technology Policy (OSTP) where she supported the President Obama’s Council of Advisors on Science and Technology (PCAST). As part of the executive secretariat for PCAST, Diana worked on a range of topics including private sector adaptation to climate change, forensic science, technology for aging, and ensuring the safety of the Nation’s drinking water.
Prior to OSTP, Diana was a program officer on the Board on Health Sciences Policy at the National Academy of Medicine where she staffed the Forum on Neuroscience and Nervous System Disorders. There she focused on a variety of issues including mental health care in sub-Saharan Africa and accelerating development of therapeutics for nervous system disorders.
Diana received her Ph.D. in neuroscience from Boston University. After graduating from Boston University, she completed a postdoctoral fellowship at the University of Pennsylvania Veterinary School. Diana has a B.S. in Biology with a concentration in neuroscience from the University of Rochester.